Pediatrics

FDA grants rare pediatric disease, orphan drug designations to retinoblastoma treatment

The U.S. Food and Drug Administration has granted rare pediatric disease and orphan drug designations to for OXU-003 (Oxular Limited) for the treatment of retinoblastoma. In preclinical models, the anti-tumor drug has been shown to be effective as a stand-alone therapy, as well as complementary to other current treatments. “I...